| Title |
Management of Inflammatory Bowel Disease in the Elderly: Do Biologicals Offer A Better Alternative?
|
|---|---|
| Published in |
Drugs & Aging, September 2013
|
| DOI | 10.1007/s40266-013-0120-x |
| Pubmed ID | |
| Authors |
Christina Ha, Seymour Katz |
| Abstract |
The management of inflammatory bowel disease (IBD) in elderly patients provides added complexity for healthcare providers who need to take into account the high likelihood of co-morbid disease, the need for polypharmacy and, in many instances, greater patient fragility. While biologics are often considered first-line corticosteroid-sparing strategies for moderate to severe disease, the additional variables unique to an elderly patient warrant consideration when discussing IBD therapeutics. As chronic corticosteroid use, although relatively common among older IBD patients, is suboptimal, the efficacy and safety of biologics compared with immunomodulators among older IBD patients needs additional investigation. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 3% |
| Unknown | 38 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 6 | 15% |
| Researcher | 6 | 15% |
| Student > Master | 5 | 13% |
| Other | 4 | 10% |
| Student > Ph. D. Student | 4 | 10% |
| Other | 5 | 13% |
| Unknown | 9 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 56% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Business, Management and Accounting | 1 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Social Sciences | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 11 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 October 2013.
All research outputs
#18,351,676
of 22,727,570 outputs
Outputs from Drugs & Aging
#1,042
of 1,193 outputs
Outputs of similar age
#151,082
of 203,071 outputs
Outputs of similar age from Drugs & Aging
#14
of 18 outputs
Altmetric has tracked 22,727,570 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,193 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 5th percentile – i.e., 5% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 203,071 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.